Ascendis Pharma Bone Diseases A/S

Hypoparathyroidism in Adults

Clinical research is centered on adult hypoparathyroidism, with attention to restoring parathyroid hormone activity and supporting calcium homeostasis. The sponsor’s studies focus on treatment approaches relevant to chronic endocrine deficiency and its metabolic consequences.

  • Serum calcium regulation
  • Urinary calcium balance
  • Active vitamin D management

Research activity in this area reflects a therapeutic interest in improving biochemical control for adults living with persistent hypocalcaemia related to hypoparathyroidism.

Chronic Hypoparathyroidism

The sponsor also studies chronic hypoparathyroidism across age groups, including adolescents, with a focus on long-term endocrine replacement and symptom control. This area includes investigation of approaches intended to address ongoing calcium-phosphate disturbances and reduce dependence on conventional supplementation.

  • Endocrine replacement
  • Mineral metabolism
  • Adolescent endocrine care

These studies place emphasis on a rare metabolic bone disease setting where sustained hormonal support is central to treatment interest.

Bone and Mineral Disorders

Research funded by the sponsor sits within bone and mineral disorder therapeutics, with particular relevance to disorders affecting calcium regulation and vitamin D dependence. The clinical focus includes biochemical endpoints that are important in the management of chronic endocrine-related skeletal disease.

  • Calcium-phosphate metabolism
  • Endocrine bone health
  • Supplementation burden

This therapeutic domain aligns with clinical interest in reducing metabolic instability associated with long-standing parathyroid insufficiency.

Pediatric and Adolescent Endocrinology

Part of the research portfolio extends to adolescents with long-term hypoparathyroidism, highlighting a pediatric endocrine focus. The sponsor’s activity in this area addresses the needs of younger patients who require ongoing management of calcium metabolism and hormone-related deficiency.

  • Adolescent hypoparathyroidism
  • Growth and endocrine support
  • Long-term metabolic control

This area reflects interest in age-specific treatment considerations within rare endocrine disease.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • A study to evaluate the safety and effects of palopegteriparatide in adolescents with chronic hypoparathyroidism

    Recruiting

    3 1 1 1
    Investigated drugs:
    France Germany Poland Romania
  • Study on the Safety and Effectiveness of TransCon PTH for Adults with Hypoparathyroidism

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany Italy Norway